Sequence: GRKKRRQRRRPPQ (with C-terminal Cys in construct: ...PPQC)
| Experiment Id | EXP001772 |
|---|---|
| Paper | Lung Delivery Studies Using siRNA Conjugated to TAT(48-60) and Penetratin Reveal Peptide Induced Red |
| Peptide | TAT(48-60) |
| Delivery Success Class | no |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | low |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | 10 nmol dose as peptide–siRNA conjugate (in 20 µL; ~500 µM) |
| Rna Concentration | 10 nmol siRNA dose (conjugated; 20 µL) |
| Mixing Ratio | covalent conjugate (N/A) |
| Formulation Format | disulfide-linked peptide–siRNA conjugate |
| Formulation Components | CPP (TAT(48-60) or penetratin) conjugated to siRNA sense strand; duplex siRNA |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | BALB/c mice (male, 20–25 g); lung (intratracheal) |
| Administration Route | Intratracheal (20 µL PBS) |
| Output Type | p38 MAPK mRNA knockdown in whole lung (RT-qPCR) |
| Output Value | ~20–30% knockdown (significant at 12 h; compared with PBS) |
| Output Units | |
| Output Notes | Authors note TAT peptide alone also reduced p38 MAPK mRNA, confounding RNA-specific attribution. |
| Toxicity Notes | No innate immune cytokine induction reported for TAT-siRNA; peptide alone affected gene expression. |
| Curation Notes |